YIPF2

Across TCGA pan-cancer cohorts, YIPF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YIPF2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher YIPF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated YIPF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where YIPF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.237	0.895	.004	43	view →
LSCC	OS	Tertile	All	0.728	0.946	.004	21	view →
CCRCC	DFS	Tertile	All	0.429	1.000	.003	18	view →
LUAD	OS	Median	III,IV	0.748	0.277	.029	2	view →
PDAC	OS	Median	III,IV	0.507	0.936	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YIPF2–HNSC (DFS)

Open the HNSC breakdown →